NCT04939142 · OUTCOME

Progression-Free Survival (PFS)

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) · Source last updated 2026-08-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: month
Interval / dispersion: 95% Confidence Interval
Time frame: From date of randomization until the date of first documented PD (per IMWG criteria) or date of death, whichever occurs first. Participants without PD or death at the time of analysis are censored at the date of their last adequate disease assessment.

What was measured

To evaluate progression-free survival

Groups in this outcome

SVd (Selinexor+Bortezomib+Dexamethasone)

Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles. SVd (Selinexor+Bortezomib+dexamethasone): Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)

Vd (Bortezomib+Dexamethasone)

Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles. Vd (Bortezomib+dexamethasone): Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
SVd (Selinexor+Bortezomib+Dexamethasone)	100
Vd (Bortezomib+Dexamethasone)	52

Reported measurements

Source class 1

Values in month · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
SVd (Selinexor+Bortezomib+Dexamethasone)	8.11	Not reported	6.28	11.99	Not reported
Vd (Bortezomib+Dexamethasone)	6.34	Not reported	5.55	11.79	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
6.28
upper Limit
11.99
value
8.11
group Id
OG001
lower Limit
5.55
upper Limit
11.79
value
6.34

denoms

counts
group Id
OG000
value
100
group Id
OG001
value
52
units
Participants

description

To evaluate progression-free survival

dispersion Type

95% Confidence Interval

groups

description
Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles. SVd (Selinexor+Bortezomib+dexamethasone): Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
id
OG000
title
SVd (Selinexor+Bortezomib+Dexamethasone)
description
Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles. Vd (Bortezomib+dexamethasone): Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
id
OG001
title
Vd (Bortezomib+Dexamethasone)

param Type

MEDIAN

reporting Status

POSTED

time Frame

From date of randomization until the date of first documented PD (per IMWG criteria) or date of death, whichever occurs first. Participants without PD or death at the time of analysis are censored at the date of their last adequate disease assessment.

title

Progression-Free Survival (PFS)

type

PRIMARY

unit Of Measure

month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice